I totally agree that a single Big Pharma would be unlikely to develop 2599 in 100+ indications. Not only unlikely but also unwilling.
For example, some indications might be considered less likely to demonstrate benefit from NNZ-2591, some might be considered to have too small a market and in some indications the competitive landscape might not be so favourable.
It's true that sometimes when Big Pharma acquires a drug, it goes nowhere. Sometimes the later data just isn't compelling enough. Sometimes the pharma will simply pay to take a competitor out of the game.
But in this instance, there’s no Big Pharma with competing marketed drugs in neurodevelopmental disorders. So there should be major motivation for any BP acquirer to go hard and go fast.
If NNZ-2591 continues to demonstrate great results in the clinic, clearly demonstrates very broad potential application, and if a big pharma has paid up big to acquire it, that pharma is likely to be willing and in the position to advance multiple trials concurrently.
For example, Roche has 118 compounds in clinical development concurrently; Pfizer has 83 with 23 in Phase 3; Astra Zeneca has 167 in its pipeline with 38 in Phase 3; Novartis 136, with 39 in Phase 3…
No matter how Neuren approaches it, it can’t compete with that level of firepower.
NEU Price at posting:
$25.13 Sentiment: Hold Disclosure: Held
(20min delay)